Additional file 1: of Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies

Autor: Mullins, Stefanie, Vasilakos, John, Deschler, Katharina, Iwen Grigsby, Gillis, Pete, John, Julius, Matthew Elder, Swales, John, Timosenko, Elina, Cooper, Zachary, Dovedi, Simon, Leishman, Andrew, Luheshi, Nadia, Elvecrog, James, Ashenafi Tilahun, Goodwin, Richard, Herbst, Ronald, Tomai, Mark, Wilkinson, Robert
Rok vydání: 2019
DOI: 10.6084/m9.figshare.9808583.v1
Popis: Supplementary Information Materials and Methods. Figure S1 In vitro characterisation of MEDI9197. Figure S2 Rat serum MEDI9197 levels following SC or IM administration. Figure S3 Local versus systemic cytokine induction following MEDI9197 administration in rodents. Figure S4 Intratumoral administration is required for MEDI9197 anti-tumor effects. Figure S5 IT administration of MEDI9197 modifies the tumor immune gene profile. Figure S6 MEDI9197 enhances NK activation and gating strategies. (DOCX 1080 kb)
Databáze: OpenAIRE